Boston Scientific Earnings Analysis

ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown! I'm Alex.JORDAN: And I'm Jordan. Today we're diving into Boston Scientific's fourth quarter and full year 2025 results - and wow, what a year it's been for this medical device giant.ALEX: Before we jump in, I need to mention that this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.JORDAN: Absolutely. So Alex, Boston Scientific just wrapped up what CEO Mike Mahoney called an "outstanding" year. Let's start with the headline numbers - they're pretty impressive.ALEX: They really are. For the full year, Boston Scientific hit over $20 billion in sales - that's 19% operational growth and nearly 16% organic growth. They actually exceeded their guidance of around 15.5%. And on the bottom line? Adjusted earnings per share of $3.06, up 22% year-over-year.JORDAN: That's their third consecutive year of 20%+ EPS growth, which is remarkable consistency in this industry. But what I found interesting was the fourth quarter specifically - 13% organic growth, which hit the high end of their guidance range. The question is, what's driving all this growth?ALEX: Two words: EP and WATCHMAN. Their electrophysiology business grew 35% in Q4 and a staggering 73% for the full year. That's largely driven by their FARAPULSE technology - basically a next-generation treatment for atrial fibrillation that uses pulsed field ablation instead of traditional methods.JORDAN: And WATCHMAN, their left atrial appendage closure device, grew 29% in the quarter. Mike Mahoney mentioned they've now treated more than 25,000 patients with what they call "concomitant procedures" - essentially doing WATCHMAN and EP procedures together, which is more efficient for hospitals.ALEX: But here's where it gets really interesting - and where some investors got a bit nervous during the earnings call. There were questions about whether growth is slowing, especially in the U.S. EP market. Some analysts were expecting even higher numbers.JORDAN: Right, and Mahoney pushed back on this pretty hard. He said competitors are claiming the EP market grew 25% in Q4, but Boston Scientific thinks it was more like 18-20%. And even at that growth rate, they're significantly outpacing competitors - some major players only grew 6.5% and 12.5% respectively.ALEX: That's a crucial point for investors. Market share dynamics are shifting as competitors launch their own PFA products, but Boston Scientific believes they'll maintain clear market leadership. Mahoney said by year-end 2026, their PFA share might equal all other competitors combined, but they'll still be the leader.JORDAN: And looking ahead, they're guiding for some pretty solid numbers in 2026. Organic revenue growth of 10-11% for the full year, though Q1 will be softer at 8.5-10% due to some one-time headwinds and tough comparisons.ALEX: Those headwinds include discontinuing a product called ACURATE and a temporary withdrawal of certain sizes of their AXIOS device due to manufacturing issues. But they expect both situations to resolve by mid-year.JORDAN: Let's talk about what could be a game-changer - the CHAMPION trial results. This is a major clinical study comparing their WATCHMAN device to blood thinners for stroke prevention. Dr. Ken Stein, their Chief Medical Officer, said results will be presented at the American College of Cardiology conference.ALEX: If positive, this could be huge. Currently, WATCHMAN is indicated for about 5 million patients globally who can't tolerate blood thinners. But if CHAMPION shows WATCHMAN is as effective as blood thinners with better bleeding outcomes, that addressable market could jump to 20 million patients.JORDAN: That would essentially position WATCHMAN as a first-line therapy instead of just for patients who caThis episode includes AI-generated content.